---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-001046"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:47:30.055405+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports Phase 3 paridiprubart cut 28-day mortality by 27% (p<0.001); 278-patient study positive

## Summary
- Paridiprubart reduced adjusted 28-day mortality to 24% from 33% (27% relative risk reduction; p<0.001) in full 278-patient population.
- Consistent benefit across severity groups: 35% reduction in non-IMV (n=174) and across comorbidities (sepsis, AKI, pneumonia).
- Safety profile favorable; adverse events low and similar to placebo; over 400 patients now exposed.
- Company filed provisional patent applications for paridiprubart in sepsis, acute kidney injury, and pneumonia.

## SEC filing metadata
- accession: 0001171843-26-001046
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184326001046/0001171843-26-001046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184326001046/f8k_021926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-001046
- JSON: https://secwatch.observer/filing/0001171843-26-001046.json
- Plain text: https://secwatch.observer/filing/0001171843-26-001046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.